Search
COPD Paid Clinical Trials in Arizona
A listing of 7 COPD clinical trials in Arizona actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 7 of 7
The state of Arizona currently has 7 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
Featured Trial
Chronic Obstructive Pulmonary Disease Study
Recruiting
This is a clinical research study to test the safety and effectiveness of an investigational medication as an add-on treatment for Chronic Obstructive Pulmonary Disease (COPD). Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated up to $85 per visit for time and travel.
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
COPD
COPD Exacerbation
Copd Exacerbation Acute
Emphysema or COPD
* Compensation for time may be available
Featured Trial
Clinical Studies for COPD
Recruiting
Clinical Studies for COPD
Conditions:
COPD
Copd Exacerbation Acute
Emphysema or COPD
COPD Asthma
Chronic Obstructive Pulmonary Disease(COPD)
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy volunteer trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/26/2024
Locations: Pulmonary Associates, Glendale, Arizona +2 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
SPIROMICS Study of Early COPD Progression (SOURCE)
Recruiting
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals.
The study has three main goals:
To use CT scan imaging to identify which smokers will develop COPD.
To identify biomarkers predictive of smokers that will develop COPD.
To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD.
Procedures (methods): All participants will undergo study related qu... Read More
Gender:
All
Ages:
Between 30 years and 55 years
Trial Updated:
03/25/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: COPD, Early-Onset
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolmen... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/22/2024
Locations: Research Site, Peoria, Arizona +1 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/19/2024
Locations: Research Site, Tempe, Arizona
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Gilbert, Arizona +7 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/07/2024
Locations: Research Site, Tempe, Arizona
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Recruiting
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/06/2023
Locations: Chiesi Clinical Trial Site 840190, Phoenix, Arizona
Conditions: COPD, COPD Exacerbation
1 - 7 of 7